Week's news analysis

Fujifilm to invest $1.6 billion
in cell culture manufacturing

By Editors - 30 June 2022
FUJIFILM Diosynth Biotechnologies - HOLLY SPRINGS Site, USA/ DR

FUJIFILM Diosynth Biotechnologies, a subsidiary of FUJIFILM Corporation, invest $1.6 billion to enhance and expand the cell culture manufacturing services. This investment will enhance FUJIFILM Diosynth Biotechnologies' sites in Hillerød, Denmark, and Texas in the United States.

As part of this investment, FUJIFILM Diosynth Biotechnologies is further expanding its capacity to support large-scale cGMP fed batch production by adding 8 x 20,000L bioreactors and two downstream processing streams in its Hillerød, Denmark facility. The additional production capacity will make the Hillerød facility the largest end-to-end CDMO in Europe, offering a total of 20 x 20,000L bioreactors for drug substance production complemented by comprehensive drug product and finished goods services. The investment is expected to create approximately 450 jobs.

The Denmark facility will be enhanced with sustainability measures to support Fujifilm's new "Green Value Climate Strategy" with climate action targets including operating on carbon-free energy and achieving net zero CO2 emissions by the end of Fiscal Year 2040. Sustainable production enhancements will include installation of an electric boiler rather than a conventional boiler powered by natural gas, thereby removing operational dependency of the site on fossil fuels. In addition, FUJIFILM Diosynth Biotechnologies is investing in programs that aim to reduce water consumption.

This investment will also expand cell culture manufacturing solutions at the FUJIFILM Diosynth Biotechnologies' Texas site. FUJIFILM Diosynth Biotechnologies will implement its proprietary SymphonXTM production equipment, enabling cGMP MaruXTM continuous processing at the single-use cell culture manufacturing site.

The company operates a global network with major locations in the Unites States of America, the United Kingdom and Denmark and it is building a new manufacturing site in Holly Springs, North Carolina, USA. FUJIFILM Diosynth Biotechnologies has over thirty years of experience in the development and manufacturing of recombinant proteins, vaccines, monoclonal antibodies, among other large molecules, viral products and medical countermeasures expressed in a wide array of microbial, mammalian, and host/virus systems.

In April, FUJIFILM Corporation has completed the acquisition of a dedicated cell therapy manufacturing facility from Atara Biotherapeutics, Inc. for USD 100 million. The facility located in Thousand Oaks, California, will be operated as part of FUJIFILM Diosynth Biotechnologies' global network.

The 90,000 sq. ft. site is readily expandable to add capacity and has the flexibility to produce both clinical and commercial cell therapies including allogeneic T-cell and CAR T immunotherapies. FUJIFILM Diosynth Biotechnologies will retain 134 employees in manufacturing and quality positions at the site.

TO READ Evonik to build $220 mln U.S. production site for mRNA lipids

Go to Top